NCT04065425: A trial that was reported late by Multiple Myeloma Research Consortium
This trial was previously reported as an Applicable Clinical Trial, but is no longer.
Full data
| Full entry on ClinicalTrials.gov | NCT04065425 |
|---|---|
| Title | A Phase I/II Assessment of Combination Immuno-Oncology Drugs Elotuzumab, Anti-LAG-3 (BMS-986016) and Anti-TIGIT (BMS-986207) |
| Results Status | no-longer-act |
| ACT or pACT? | This is what FDAAA officially calls an "Applicable Clinical Trial" |
| Start date | Oct. 1, 2019 |
| Completion date | Oct. 1, 2023 |
| Required reporting date | Sept. 30, 2024, midnight |
| Actual reporting date | None |
| Date last checked at ClinicalTrials.gov | Aug. 3, 2020 |
| Days late | None |